University of Oxford scientists developed extremely rapid diagnostic test for Covid-19
On Oct. 15, 2020, scientists from the University of Oxford ï¾’s Department of Physics announced they had developed…
Eiger announced positive results of randomized controlled trial with Peginterferon lambda in outpatients with COVID-19
On Oct. 15, 2020, Eiger BioPharmaceuticals announced results of the ILIAD Study (Interferon Lambda for Immediate Antiviral Therapy…
FDA authorized phase 1 trial of ImmunityBioï¾’s novel COVID-19 vaccine candidate hAd5 to drive T cell and antibody immunity
On Oct. 15, 2020, ImmunityBio announced it had received authorization from the FDA to begin a Phase I…
Ionis antisense medicine evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
On Oct. 15, 2020, Ionis Pharmaceuticals announced that IONIS-PKK-LRx was being evaluated in an investigator-initiated Phase 2 clinical…
Tonix Pharmaceuticals enrolled first participant in PRECISION Study for COVID-19 vaccines and therapeutics
On Oct. 15, 2020, Tonix Pharmaceuticals announced that the first participant was enrolled in the observational PRECISION study…
Fred Hutch completed move-in of Lake Union Steam Plant
On Nov. 9, 2020, after more than two years of reconstruction efforts, scientists from the Fred Hutchinson Cancer…
Projects launched to map the nucleus, the information center of our cells
On Oct. 15, 2020 teams from two divisions of the Allen Institute, the Allen Institute for Cell Science…
Brazilian Health Regulatory Agency authorized Sorrento’s phase 2 clinical trial of Abivertinib in COVID-19 patients
On Oct. 14, 2020, Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed…
COVID-19 | Disease | Life Science News | WHO
Global tuberculosis progress at risk during COVID-19 pandemic
On Oct. 14, 2020, the World Health Organization (WHO) announced that prior to the COVID-19 pandemic, many countries…
WHO announced position on genetically modified mosquitoes
On Oct. 14, 2020, recognizing the urgent need for new tools to combat vector-borne diseases (VBDs), and in…
FDA approved first treatment for Ebola virus
On Oct. 14, 2020, the FDA approved Regeneron Pharmaceutical’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three…
US DOD expanded collaboration with AstraZeneca to develop and manufacture an investigational mab to prevent COVID-19
On Oct. 14, 2020, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD)…
Vaxart announced positive hamster challenge study data for its oral COVID-19 vaccine
On Oct. 14, 2020, Vaxart announced that the FDA had completed its review of the Companyï¾’s Investigational New…
Thermo Fisher announced plans to expand sterile filling capacity for therapies and vaccines with new facility in Singapore
On Oct. 14, 2020, Thermo Fisher Scientific announced plans to develop two new sterile filling lines in Singapore…
Moderna received confirmation of eligibility for submission of MAA to the European Medicines Agency for COVID-19 vaccine
On Oct. 14, 2020, Moderna announced that it had received written confirmation from the European Medicines Agency (EMA)…
Americaï¾’s Top Young Scientist of 2020: 14-year-old researched spike protein of SARS-CoV-2 virus
On Oct. 14, 2020, 3M and Discovery Education anounced they had named 14-year-old Anika Chebrolu from Frisco, Texas,…
Novanï¾’s NITRICILï¾™ technology showed In vitro antiviral effect against SARS-CoV-2 in human airway infection model
On Oct. 14, 2020, Novan announced positive in vitro results showing the potential efficacy of its NITRICILï¾™ platform…
Tevogen Bio submitted IND for T cell treatment in COVID-19
On Oct. 14, 2020, Tevogen Bio announced that its Investigational New Drug (IND) application to develop a COVID-19…
Regeneron’s antibody cocktail REGN-EB3 (Inmazeb) first FDA-approved treatment for Ebola (Zaire Ebolavirus)
On Oct. 14, 2020, Regeneron announced that the FDA had approved Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) for the…
Pfizer and BioNTech announced publication of phase 1 data on lead mRNA vaccine candidate against COVID-19
On Oct. 14, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from the Phase 1 portion of…
Mosquitoes’ taste for blood traced to four types of neurons
On Oct. 13, 2020, Howard Hughes Medical Institute Investigator Leslie Vosshall’s team at The Rockefeller University and colleagues…
DOD awarded $481 million to Cue Health to increase domestic production capacity of point-of-care testing
On Oct. 13, 2020, the Department of Defense (DOD), on behalf of the U.S. Department of Health and…
COVID-19 vaccine with Dynavaxï¾’s CpG 1018 adjuvant received Taiwan government subsidy with first dosage
On Oct. 13, 2020, Medigen Vaccine Biologics (MVC) and Dynavax Technologies announced that MVC had obtained a Taiwan…
NIH launched its ACTIV-5 ‘Big Effect Trial’ evaluating Humanigen’s Lenzilumabas potential COVID-19 therapy
On Oct. 13, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases (NIAID), had launched…
NIH-funded study linked adolescent brain differences to increased waist circumference
On Oct. 13, 2020, the National Institute on Drug Abuse (NIDA) and nine other institutes, all part of…
Roche launched laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
On Oct. 13, 2020, Roche announced that it intended to launch a high-volume SARS-CoV-2 Antigen test as an…
NIH study to identify promising COVID-19 treatments for larger clinical trials
On Oct. 13, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), launched a study designed to…
NeoGenomics expanded global footprint in pharma services with new clinical research laboratory in Suzhou, China
On Oct. 13, 2020, NeoGenomics announced plans to open a state-of-the-art research laboratory in China in association with…
RedHill Biopharma announced partnerships to expand manufacturing for COVID-19 therapeutic candidate opaganib
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
Apogenix advanced clinical development of CD95L inhibitor asunercept in European COVID-19 phase II trial
On Oct. 13, 2020, Apogenix announced that the first patient has been enrolled in the ASUNCTIS trial. The…